US20010004395A1 - Fiducial marker - Google Patents
Fiducial marker Download PDFInfo
- Publication number
- US20010004395A1 US20010004395A1 US09/742,411 US74241100A US2001004395A1 US 20010004395 A1 US20010004395 A1 US 20010004395A1 US 74241100 A US74241100 A US 74241100A US 2001004395 A1 US2001004395 A1 US 2001004395A1
- Authority
- US
- United States
- Prior art keywords
- marker
- fiducial
- imaging
- imageable
- fiducial marker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003550 marker Substances 0.000 title claims abstract description 172
- 238000003384 imaging method Methods 0.000 claims abstract description 85
- 238000002595 magnetic resonance imaging Methods 0.000 claims abstract description 41
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 16
- 239000000463 material Substances 0.000 claims description 33
- 239000000243 solution Substances 0.000 claims description 21
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims description 18
- 210000003484 anatomy Anatomy 0.000 claims description 17
- 210000000988 bone and bone Anatomy 0.000 claims description 16
- 239000007864 aqueous solution Substances 0.000 claims description 13
- 229910052751 metal Inorganic materials 0.000 claims description 13
- 239000002184 metal Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 12
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 10
- 239000011630 iodine Substances 0.000 claims description 10
- 229910052740 iodine Inorganic materials 0.000 claims description 10
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 10
- 229910001961 silver nitrate Inorganic materials 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- VLHUSFYMPUDOEL-WZTVWXICSA-N Iothalamate meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I VLHUSFYMPUDOEL-WZTVWXICSA-N 0.000 claims description 7
- 229940029379 iothalamate meglumine Drugs 0.000 claims description 7
- 230000005291 magnetic effect Effects 0.000 claims description 7
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 7
- 229910052788 barium Inorganic materials 0.000 claims description 5
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims description 5
- 238000002513 implantation Methods 0.000 claims description 5
- 229910052697 platinum Inorganic materials 0.000 claims description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- 229910052709 silver Inorganic materials 0.000 claims description 4
- 239000004332 silver Substances 0.000 claims description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical group O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 3
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical class [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052737 gold Inorganic materials 0.000 claims description 3
- 239000010931 gold Substances 0.000 claims description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 3
- 238000009877 rendering Methods 0.000 claims description 3
- 229910052715 tantalum Inorganic materials 0.000 claims description 3
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 claims description 3
- 229910052719 titanium Inorganic materials 0.000 claims description 3
- 239000010936 titanium Substances 0.000 claims description 3
- 229920001903 high density polyethylene Polymers 0.000 claims description 2
- 239000004700 high-density polyethylene Substances 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims description 2
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 claims description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 2
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 229910001928 zirconium oxide Inorganic materials 0.000 claims description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 1
- 229960003194 meglumine Drugs 0.000 claims 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims 1
- 239000012216 imaging agent Substances 0.000 abstract description 40
- 238000002591 computed tomography Methods 0.000 abstract description 6
- 238000013170 computed tomography imaging Methods 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 230000003902 lesion Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 9
- 238000001356 surgical procedure Methods 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 229940005649 gadopentetate Drugs 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 5
- IZOOGPBRAOKZFK-UHFFFAOYSA-K gadopentetate Chemical compound [Gd+3].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O IZOOGPBRAOKZFK-UHFFFAOYSA-K 0.000 description 5
- 238000001959 radiotherapy Methods 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000002872 contrast media Substances 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 150000002739 metals Chemical class 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 3
- 229960001025 iohexol Drugs 0.000 description 3
- 229920000620 organic polymer Polymers 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
- 230000005408 paramagnetism Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000022211 Arteriovenous Malformations Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 241000284156 Clerodendrum quadriloculare Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 239000002616 MRI contrast agent Substances 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 239000004697 Polyetherimide Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000005744 arteriovenous malformation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000000071 blow moulding Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000007428 craniotomy Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005307 ferromagnetism Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011404 fractionated radiotherapy Methods 0.000 description 1
- -1 gadopentetate compound Chemical class 0.000 description 1
- 229940044350 gadopentetate dimeglumine Drugs 0.000 description 1
- LGMLJQFQKXPRGA-VPVMAENOSA-K gadopentetate dimeglumine Chemical group [Gd+3].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O LGMLJQFQKXPRGA-VPVMAENOSA-K 0.000 description 1
- DPNNNPAKRZOSMO-UHFFFAOYSA-K gadoteridol Chemical group [Gd+3].CC(O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 DPNNNPAKRZOSMO-UHFFFAOYSA-K 0.000 description 1
- 229960005451 gadoteridol Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002907 paramagnetic material Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001601 polyetherimide Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
- A61B2090/3904—Markers, e.g. radio-opaque or breast lesions markers specially adapted for marking specified tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
- A61B2090/3995—Multi-modality markers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
Definitions
- Imaging systems such as computed tomographic (CT) x-ray imagers, positron emission tomographic (PET) scanners, single photon emission computed tomography (SPECT) scanners and nuclear magnetic resonance imaging (MRI) machines have provided clinicians with the ability to improve visualization of the anatomical structure of the human body without surgery or other invasive techniques.
- CT computed tomographic
- PET positron emission tomographic
- SPECT single photon emission computed tomography
- MRI nuclear magnetic resonance imaging
- the patient can be subjected to the scanning modalities of such imaging systems, and the patient's anatomical structure can be reproduced in a form for evaluation by a trained doctor.
- the doctor sufficiently experienced in these techniques can evaluate the images of the patient's anatomy and determine if there are any abnormalities present.
- An abnormality in the form of a lesion appears on the image as a shape that has a discernable contrast with the surrounding area.
- the difference in contrast is due to the lesion having imaging properties that differ from those of the surrounding body tissue.
- the contrasting shape that represents the lesion appears at a location on the image where such a shape would not normally appear with regard to a similar image of a healthy person.
- a problem associated with the scanning techniques mentioned above concerns the accurate selection and comparison of views of identical areas in images that have been obtained by imagers at different times or by images obtained essentially at the same time using different image modalities, e.g., CT, MRI, SPECT, and PET.
- This problem has two aspects. First, in order to relate the information in an image of the anatomy to the anatomy itself, it is necessary to establish a one-to-one mapping between points in the image and points on the anatomy. This is referred to as registering image space to physical space.
- the second aspect concerns the registration of one image space to another image space.
- the goal of registering two arbitrarily oriented three dimensional images is to align the coordinate systems of the two images such that any given point in the scanned anatomy is assigned identical addresses in both images.
- the calculation of the rigid body transformation necessary to register the two coordinate systems requires knowledge of the coordinate vectors of at least three points in the two systems. Such points are called “fiducial points” or “fiducials,” and the fiducials used are the geometric centers of markers, which are called “fiducial markers”.
- These fiducials are used to correlate image space to physical space and to correlate one image space to another image space.
- the fiducial markers provide a constant frame of reference visible in a given imaging mode to make registration possible.
- the general technique for using fiducial markers to obtain registration of image data across time is set forth in U.S. Pat. No. 4,991,579 to George S. Allen, the contents of which are incorporated herein by reference.
- MRI and X-ray CT images are digital images, in which the images are formed point by point. These points are called picture elements, or pixels, and are associated with an intensity of light emitted from a cathode ray tube, or are used to form an image on film.
- the array of lighted pixels enables the observer to view an image.
- the manner in which the intensity of any given pixel is altered or modulated varies with the imaging modality employed. In X-ray CT, such modulation is a function primarily of the number of electrons per unit volume being scanned.
- a further problem in the field arises from the competing needs of accommodating patient comfort, which would tend to lead clinicians toward the minimization of marker size, with the desire of clinicians to use markers that are as bright and thus as large as possible.
- Such brightness is desirable because it provides a strong signal that can be distinguished from noise inherent in the imaging process.
- the use of large-sized markers is also desirable so that the image of the marker occupies as many pixels as possible. Increasing the number of pixels occupied by the marker increases the accuracy with which the position of the marker can be determined.
- the general technique of using fiducial markers requires the determination of the centroid of the marker; it is easier to compute the centroid for a large, bright marker than for a smaller, dimmer marker.
- a marker which can exploit the advantages presented by increased size that would also be tolerated by the patient during the period of its use.
- a small multi-modality marker that can be implanted into a patient and remain there for more extended periods of time.
- Such a more permanent fiducial marker would preferably be detectable by a non-invasive technique so that its position in physical space could be determined and its centroid computed even as it remained hidden from visual inspection beneath the patient's skin.
- a fiducial marker having features of the present invention includes a hollow container, preferably cylindrical or spherical, that may be made of imageable material and which is filled with liquids suitable for various imaging modalities.
- the marker is of suitably compact size and shape to be implanted into bone for periods of prolonged duration that may be measured in years.
- a cylindrical shape is preferred, as it minimizes the size of the incision required for insertion by maximizing the available volume of contrast agent for a given incision size.
- a permanently implanted marker allows comparison of scans over time for follow-up therapy (for example, to make lesion volume comparisons in order to monitor growth). It also allows fractionated radiotherapy, in which small doses of radiation are administered frequently over the course of treatment.
- the container is charged with aqueous imaging agents to provide imaging capability in MRI.
- CT imaging capability may be provided in either of two ways: by doping the plastic housing with agents that will render the marker housing imageable under CT, in which case the shape of the housing so doped is such that its volume centroid is coincident with the center of the volume occupied by the MRI imaging agent, or by mixing the aqueous MRI imaging agents with other aqueous agents imageable under CT. Additionally, both ways may be employed in the same marker.
- the imaging agents are selected so as to provide suitable imaging in both modalities and, where an aqueous CT imaging agent is employed, must be miscible.
- FIG. 1B shows the marker of FIG. 1 a as assembled
- FIG. 2A is an elevational view of the fiducial marker assembly, in which the imaging marker is shown attached to the base;
- FIG. 2B illustrates in cross section the invention shown in FIG. 2A as viewed along line A-A;
- FIG. 3A is an elevational view of the base portion of the invention.
- FIG. 3C is a cross sectional view of the base taken along line C-C showing the grooves that receive the imaging marker
- FIG. 4B is a top plan view of the cap portion shown in FIG. 4A;
- FIG. 4C is a bottom plan view of the cap.
- FIGS. 1 - 4 a version of a temporary fiducial marker assembly is indicated in FIGS. 1 - 4 .
- FIGS. 1 - 4 These figures illustrate a fiducial marker assembly comprising an imaging marker 10 and a base 30 .
- the imaging marker portion of the temporary fiducial marker assembly may consist of two principal portions, a cylinder 12 and a cap 16 (see FIGS. 4A - 4 C).
- the cylinder 12 contains a cavity 14 for receiving a mixture of imaging agents whose composition is determined by the imaging modalities to be employed. While in this version, the vessel containing the imaging agents is preferably cylindrical so as to simplify the process by which the centroid of the corresponding volume of imaging agent is determined, other shapes (such as a box or sphere) could be employed as well.
- the cylinder 12 is closed at one end and open at the other to allow for the introduction of the imaging agents.
- a cap 16 is used to seal off the open end of the cylinder once the imaging agents have been added to the cylinder.
- a cap may be provided with a protruding boss 20 and a plurality (here, three) of snap arms 18 , which terminate with inwardly projecting portions 22 .
- the shape and dimensions of the boss are in direct correspondence with the shape and size of the socket 36 provided in the base 30 so as to properly and securely center the imaging marker on the base.
- the snap arms 18 cooperate with the grooves 34 of the base 30 so as to detachably secure the imaging marker onto the base.
- FIGS. 2 a and 2 b shows the use of snap arms, other fastener structure may be provided for attaching the marker to the base (e.g., screw threads, clasps, hooks, etc.).
- the dimensions of the temporary fiducial marker assembly will be somewhat dependent on the state of the art of imaging.
- the Applicants have found that a base portion approximately 12 mm in length and 2 mm-3 mm in diameter is sufficiently large to provide for the secure placement of the base into the bone beneath the skin.
- an imaging marker approximately 6 mm in length is attached to the base; the marker itself may protrude from the scalp and be exposed to air while a scan is performed on the patient.
- the base and the imaging marker housing are constructed of a bio-compatible organic polymer, such as polyether imide.
- FIG. 5 illustrates a second embodiment of the fiducial marker, which may be left implanted entirely beneath the skin for extended periods of time.
- the marker comprises a cylinder 42 defining a space into which is placed one or more desired imaging agents.
- a cylindrical shape is preferred, because this shape minimizes the size of the incision that must be made for the marker's insertion. It is also the shape that best corresponds to the hole that one drills in the bone to accommodate the marker.
- the body of the cylinder is sealed off with a cap 46 or is otherwise sealed.
- the body is preferably constructed of an organic polymer known to be well tolerated by the body for extended periods of time, such as polymethyl methacrylate, high density polyethylene, or ceramics such as zirconium oxide and aluminum oxide.
- the entire marker assembly is small enough for long-term implantation into bone without causing distortion of the bone over time.
- One exemplary size provides for the marker to be 4 mm in length and 3 mm in diameter.
- aqueous imaging agents allows for the construction of a marker that is visible under both CT and MRI imaging modalities. Furthermore, by using a marker that comprises a solid outer portion and an aqueous inner portion, the marker can be located through the use of a non-invasive transcutaneous detection system, such as one employing ultrasound to detect the presence of the solid-liquid interface between the aqueous core and the solid outer portion.
- a non-invasive transcutaneous detection system such as one employing ultrasound to detect the presence of the solid-liquid interface between the aqueous core and the solid outer portion.
- metals have been used in the past as CT markers, they are often generally less than optimal because the high linear attenuation of metals may cause unwanted image artifacts, such as starbursts. While these artifacts can be reduced somewhat by reducing the size of the markers, this reduction in size also reduces the accuracy with which the location of the marker can be determined.
- metals cause disturbances in the local magnetic field (the so-called “susceptibility” artifact) which diminish the image intensity and physically shift the position of the image. Such physical phenomena are unsuitable in a fiducial marker.
- the choice of materials selected as imaging agents is therefore driven by the physics underlying the image modalities that are employed.
- the brightest anatomical features imaged are bone, which attenuates X-rays more strongly than other tissue.
- This attenuation is characterized by the so-called “linear attenuation coefficient,” which measures the X-ray attenuation per unit of path length.
- the linear attenuation coefficient increases with increasing electron density (the number of electrons per unit of volume).
- the material being scanned must have an electron density that is greater than that of bone. Therefore, one approach to enhancing the absorption of X-rays is to increase the electron density per unit volume.
- the housing for the marker which is normally made of organic polymers, can have barium added as a salt.
- titanium dioxide may be added to the polymeric housing.
- Salts of gold or of platinum are also effective materials for rendering the housing shell radio-opaque and thus imageable under CT scanning. Concentrations of these metal salts of up to about 400 mg/ml can be used in the markers without causing appreciable image artifacts.
- Aqueous solutions of compounds having high Z atoms such as barium, iodine, titanium, tantalum, silver, platinum, and iron can be used as imaging agents in the fiducial marker of this invention.
- compounds of iodine and silver have been found to be effective for this purpose.
- an aqueous solution of an iodine containing organic molecule with an effective iodine concentration of between about 50 to about 600 mg/ml provides an effective CT imaging agent.
- silver nitrate dissolved in water at concentrations of between about 100 mg/ml to about 600 mg/ml is effective. Either solution will be effective in CT at imaging the volume defined by the marker cavity.
- aqueous solutions where only CT imaging is contemplated is optional—other carriers, such as oils, could be used as carriers for high Z-number elements.
- other carriers such as oils
- MRI magnetic resonance imaging
- aqueous imaging agent The accurate location of MRI markers in biological tissue must be done with an aqueous imaging agent. Substances other than water exhibit different resonance frequencies, or chemical shifts, and will appear in the image displaced from their true location. Therefore, where a common liquid carrier is to be used both for CT as well as MRI imaging agents, it should be water.
- I signal intensity
- N spin density
- the parameters TR and TE are the repetition time and the echo time determined by the radio frequency and gradient pulses employed
- C is a constant of proportionality that depends on the scanner and the pulses employed.
- T 1 , T 2 , and spin density can be altered by the addition of chemicals selected for their physical properties in solution.
- One such property is paramagnetism, in which the added material has an unpaired electron in its electron configuration. Such agents shorten the relaxation times T 1 and T 2 drastically.
- Another such property is viscosity.
- Other chemicals may be added to the solution for their ability to alter the viscosity of a solution, even to a point of making a gel.
- viscosity is an important consideration, because it is inversely correlated with T 2 . The more viscous a solution, the greater the number of bonds that are present and the less able the hydrogen nuclei are to react and respond to the magnetic field, which results in a dimmer image.
- These viscosity enhancing agents dilute the water in the solution, thereby reducing the spin density, and reduce the relaxation times T 1 and T 2 . Whatever the added material, T 1 will always be equal to or greater than T 2 .
- MRI imaging agents appropriate for MRI enhancements, these agents have no significant effect on the CT imaging agent.
- efficacy of an MRI imaging agent may be obscured by the presence of a CT imaging agent.
- the MR image is modulated by the cumulative effects of all solutes added to an aqueous medium. This modulation is due to interactions with the hydrogen atoms in water which provide the MR signal.
- the general effects of three typical CT imaging agents, of one typical MR imaging agent, and of selected combinations of these two types of agents are presented below.
- silver nitrate which, as noted above, provides a suitable image under CT scans when provided in concentrations up to about 600 mg/ml, reduces the observed spin density (and hence reduces the brightness of the MR image) by up to 50%.
- concentrations up to about 600 mg/ml reduces the observed spin density (and hence reduces the brightness of the MR image) by up to 50%.
- the observed T 1 and T 2 values are about 1 second.
- the concentration of silver nitrate decreases, the T 1 and T 2 values approach those of pure water. This observed effect affords the opportunity to provide a variety of marker compositions based on silver nitrate (as the CT agent) to create differing contrast levels with respect to human tissue under MRI.
- a solution of iothalamate meglumine (an ionic X-ray CT imaging agent) in concentrations up to about 600 mg/ml of iodine reduces the observed spin density by factors ranging up to 75%.
- the observed T 1 value is 1200-1500 milliseconds
- the observed T 2 value is 300-350 milliseconds.
- the solution is not viscous at this concentration.
- iothalamate meglumine may be used to provide a variety of marker compositions to create different contrast with respect to human tissue.
- T 1 and T 2 values of these altered solutions range from 1 millisecond to 4 seconds, while the spin density ranges from 0 molar (no water at all) to 111 molar in hydrogen (pure water).
- the instant invention identifies a number of substances suitable for use in MRI imaging in fiducial markers.
- One preferred suitable MRI imaging agent is gadopentetate dimeglumine.
- Another possible MRI imaging agent is gadoteridol.
- MRI imaging agents include Ferric Chloride (FeCl 3 ) and Copper Sulfate (CuSO 4 ) in concentrations of between 0.5 mM and 5 mM.
- FeCl 3 Ferric Chloride
- CuSO 4 Copper Sulfate
- iothalamate meglumine at a concentration of 175 mg/ml combined with gadopentetate meglumine-DPTA at 0.5 mM creates a solution with the following MR properties: a spin density corresponding to 75-80 molar water, T 1 value of 400-500 milliseconds, and a T 2 value of 150-200 milliseconds.
- T 1 and T 2 values permit one to create many different ratios of spin density, T 1 and T 2 values.
- the present invention may be embodied in other specific forms without departing from its spirit or essential characteristics.
- the aqueous solutions used as the carrier for the imaging agents could have the characteristics of a gel.
- the imaging agents could be provided as mixtures of three or more compounds selected to optimize particular imaging characteristics.
- the present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. For example, a flatter, more disk-like marker than that which is shown in the figures may be employed. Increasing the largest dimension of X-ray traversal boosts the brightness of the image in CT. It also allows one to take CT scans with thicker slices in which the image of the marker does not become lost in the corresponding pixel. This is especially useful in trauma cases, when there is not sufficient time for more refined views.
- the imaging agents discussed above can be relied upon for one imaging mode and another technique relied on for locating the marker in a second imaging mode.
- a first modality e.g., MRI
- a second imaging modality e.g., CT
- robotic arms such as are disclosed in U.S. Pat. No. 5,142,930 (the contents of which are herein incorporated by reference) or U.S. Pat. No.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Physics & Mathematics (AREA)
- High Energy & Nuclear Physics (AREA)
- Biophysics (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Apparatus For Radiation Diagnosis (AREA)
Abstract
Description
- Recent years have seen the development of diagnostic techniques that allow the practicing clinician to obtain high fidelity views of the anatomical structure of the human body. Imaging systems such as computed tomographic (CT) x-ray imagers, positron emission tomographic (PET) scanners, single photon emission computed tomography (SPECT) scanners and nuclear magnetic resonance imaging (MRI) machines have provided clinicians with the ability to improve visualization of the anatomical structure of the human body without surgery or other invasive techniques. In lieu of exploratory surgery, the patient can be subjected to the scanning modalities of such imaging systems, and the patient's anatomical structure can be reproduced in a form for evaluation by a trained doctor.
- The doctor sufficiently experienced in these techniques can evaluate the images of the patient's anatomy and determine if there are any abnormalities present. An abnormality in the form of a lesion appears on the image as a shape that has a discernable contrast with the surrounding area. The difference in contrast is due to the lesion having imaging properties that differ from those of the surrounding body tissue. Moreover, the contrasting shape that represents the lesion appears at a location on the image where such a shape would not normally appear with regard to a similar image of a healthy person.
- Once a lesion has been identified, several methods of treatment are utilized to remove or destroy the lesion, including chemotherapy, radiation therapy, and surgery. When chemotherapy is chosen, drugs are introduced into the patient's body to destroy the lesion. During the course of treatment, imagers are commonly used to follow the progress of treatment by subjecting the patient to periodic scans and comparing the images taken over the course of the treatment to ascertain any changes in the lesion configurations.
- In radiation therapy, the images of the lesion generated by the imager are used by a radiologist to adjust the irradiating device and to direct radiation solely at the lesion while minimizing or eliminating adverse effects to surrounding healthy tissue. During the course of the radiation treatment, the imaging system is also used to follow the progress of the patient in the same manner described above with respect to chemotherapy.
- When surgery is used to remove a lesion or other abnormality, the images of the lesion in the patient can guide the surgeon during the operation. By reviewing the images prior to surgery, the surgeon can decide the best strategy for reaching and biopsying, excising, or otherwise manipulating the abnormality or lesion, whether it is a brain tumor, arteriovenous malformation, infection or other entity. After surgery has been performed, further scanning is utilized to evaluate the success of the surgery and the subsequent progress of the patient.
- A problem associated with the scanning techniques mentioned above concerns the accurate selection and comparison of views of identical areas in images that have been obtained by imagers at different times or by images obtained essentially at the same time using different image modalities, e.g., CT, MRI, SPECT, and PET. This problem has two aspects. First, in order to relate the information in an image of the anatomy to the anatomy itself, it is necessary to establish a one-to-one mapping between points in the image and points on the anatomy. This is referred to as registering image space to physical space.
- The second aspect concerns the registration of one image space to another image space. The goal of registering two arbitrarily oriented three dimensional images is to align the coordinate systems of the two images such that any given point in the scanned anatomy is assigned identical addresses in both images. The calculation of the rigid body transformation necessary to register the two coordinate systems requires knowledge of the coordinate vectors of at least three points in the two systems. Such points are called “fiducial points” or “fiducials,” and the fiducials used are the geometric centers of markers, which are called “fiducial markers”. These fiducials are used to correlate image space to physical space and to correlate one image space to another image space. The fiducial markers provide a constant frame of reference visible in a given imaging mode to make registration possible. The general technique for using fiducial markers to obtain registration of image data across time is set forth in U.S. Pat. No. 4,991,579 to George S. Allen, the contents of which are incorporated herein by reference.
- One problem extant in the field lies in the provision of fiducials capable of use with several imaging modalities. MRI and X-ray CT images are digital images, in which the images are formed point by point. These points are called picture elements, or pixels, and are associated with an intensity of light emitted from a cathode ray tube, or are used to form an image on film. The array of lighted pixels enables the observer to view an image. The manner in which the intensity of any given pixel is altered or modulated varies with the imaging modality employed. In X-ray CT, such modulation is a function primarily of the number of electrons per unit volume being scanned. In MR imaging, the parameters primarily influencing this modulation are the proton spin density and longitudinal and transverse relaxation times T1 and T2, which are also known as the spin-lattice and spin-spin relaxation times, respectively. In constructing a fiducial marker, one must be aware that an agent that can be imaged under one imaging modality will not necessarily be imageable under another modality. And yet, the ability to image under both CT and MRI with a given marker would be especially useful, in that one would then be able to register images derived from different imaging modalities. For example, the capability to register CT and MR images would allow the integration of information concerning bony structure provided by a CT scan with the soft tissue anatomical information provided by an MRI scan. There remains a need for a fiducial marker that can be used to establish a known coordinate system under several imaging modalities.
- A further problem in the field arises from the competing needs of accommodating patient comfort, which would tend to lead clinicians toward the minimization of marker size, with the desire of clinicians to use markers that are as bright and thus as large as possible. Such brightness is desirable because it provides a strong signal that can be distinguished from noise inherent in the imaging process. The use of large-sized markers is also desirable so that the image of the marker occupies as many pixels as possible. Increasing the number of pixels occupied by the marker increases the accuracy with which the position of the marker can be determined. Furthermore, the general technique of using fiducial markers requires the determination of the centroid of the marker; it is easier to compute the centroid for a large, bright marker than for a smaller, dimmer marker. On the other hand, the larger the marker is, the more difficult it is for the patient to tolerate its presence for extended periods of time. There remains a need for a marker which can exploit the advantages presented by increased size that would also be tolerated by the patient during the period of its use. There is also a need for a small multi-modality marker that can be implanted into a patient and remain there for more extended periods of time. Such a more permanent fiducial marker would preferably be detectable by a non-invasive technique so that its position in physical space could be determined and its centroid computed even as it remained hidden from visual inspection beneath the patient's skin.
- In view of the foregoing needs, the present invention provides medical workers with fiducial markers that can be imaged under a variety of imaging modalities, i.e., are multi-modal. The markers can be used to register image space onto image space across imaging modalities. The fiducial marker may also be used for the registration of imaging space and physical space for the successful performance of image guided craniotomies, biopsies, cyst aspirations, radiation therapy, ventricular shunt placements, and other similar surgeries.
- A fiducial marker having features of the present invention includes a hollow container, preferably cylindrical or spherical, that may be made of imageable material and which is filled with liquids suitable for various imaging modalities. In one version, the marker is of suitably compact size and shape to be implanted into bone for periods of prolonged duration that may be measured in years. A cylindrical shape is preferred, as it minimizes the size of the incision required for insertion by maximizing the available volume of contrast agent for a given incision size. A permanently implanted marker allows comparison of scans over time for follow-up therapy (for example, to make lesion volume comparisons in order to monitor growth). It also allows fractionated radiotherapy, in which small doses of radiation are administered frequently over the course of treatment.
- One known measure for defining known set of points about the human skull for this purpose involves the use of a stereotactic frame (see U.S. Pat. No. 4,608,977 for a general description of such a device). At present, a stereotactic frame cannot be used for this therapy because the frame poses a significant risk of infection, is too painful, or is too bulky and restrictive to be left on for an extended time and cannot be re-attached in the same location to tolerance of submillimetric accuracy. This problem is resolved by the use of an implantable marker that can be well tolerated by the patient for extended periods of time. Such an implantable fiducial marker can also be localized in the radiation therapy suite and thereby enable the patient's image space, intracranial physical space, and radiation therapy device to be registered with each other.
- In another embodiment, the fiducial marker takes the form of a relatively larger temporary marker that is removably attached to a base that is rigidly affixed to bone. In this embodiment, the base portion is left in place for a period of days or weeks and is provided with means for detachably receiving an imaging marker. By permitting the removal of the imaging marker after scanning, the over-all height profile of the subcutaneous marker base is reduced, adding to its overall stability during implantation. In this way, the imaging marker, which need only be kept in place attached to its base for the few hours required for the medical procedure, can be made larger than could otherwise be tolerated in the case of markers left in place for days on end. The larger imaging marker produces a brighter image and is easier to localize in image space than would be the case for a smaller marker.
- The interchangeable nature of this marker also makes it suitable for use with PET and/or SPECT scans. In both of these modalities, an image marker must be radioactive. Furthermore, in both of these modalities, it is necessary to obtain with each imaging scan a so-called “transmission scan,” in which no radioactive substance is present. The transmission scan must be obtained with the patient in the same position as the imaging scan, and it is therefore not feasible for the marker bases to be implanted between scans. Instead, it is necessary to attach a nonradioactive marker for the transmission scan and then to replace the nonradioactive marker with a radioactive one for the imaging scan. The visibility of the markers in CT, MRI, PET, and SPECT images allows one to register images obtained with any of these modalities.
- In both the temporary and the more permanent versions of the invention, the container is charged with aqueous imaging agents to provide imaging capability in MRI. CT imaging capability may be provided in either of two ways: by doping the plastic housing with agents that will render the marker housing imageable under CT, in which case the shape of the housing so doped is such that its volume centroid is coincident with the center of the volume occupied by the MRI imaging agent, or by mixing the aqueous MRI imaging agents with other aqueous agents imageable under CT. Additionally, both ways may be employed in the same marker. The imaging agents are selected so as to provide suitable imaging in both modalities and, where an aqueous CT imaging agent is employed, must be miscible. The use of a miscible liquid combination results in the same volume being visible in different imaging modalities with coincident centers for the purpose of locating the center of the marker. In the embodiment for PET and/or SPECT, and external marker is filled with the appropriate radioisotope and used in place of the MRI/CT markers described in the previous paragraph. In an alternative embodiment employing the temporary fiducial marker, a kit of markers can be provided in which each marker is optimized for one imaging modality (MRI, CT, PET, or SPECT).
- For a more complete understanding of this invention, reference should now be made to the embodiments illustrated in greater detail in the accompanying drawings and described below. In the drawings:
- FIG. 1A is an exploded perspective view of a temporary fiducial marker embodying features of the present invention, in which the imaging marker is shown separated from the base with respect to which it can releasably be attached;
- FIG. 1B shows the marker of FIG. 1a as assembled;
- FIG. 2A is an elevational view of the fiducial marker assembly, in which the imaging marker is shown attached to the base;
- FIG. 2B illustrates in cross section the invention shown in FIG. 2A as viewed along line A-A;
- FIG. 3A is an elevational view of the base portion of the invention;
- FIG. 3B is a view of the top portion of the base;
- FIG. 3C is a cross sectional view of the base taken along line C-C showing the grooves that receive the imaging marker;
- FIG. 4A is an elevational view of the cap portion of the imaging marker;
- FIG. 4B is a top plan view of the cap portion shown in FIG. 4A;
- FIG. 4C is a bottom plan view of the cap; and
- FIG. 5 is a cross sectional view of a different version of the invention.
- Referring now specifically to the drawings, wherein like numerals indicate like parts throughout, a version of a temporary fiducial marker assembly is indicated in FIGS.1 - 4. These figures illustrate a fiducial marker assembly comprising an
imaging marker 10 and abase 30. - The
base 30 has a threadedportion 32 at a first end. The threads enable a surgeon to securely attach the base into the skull or other desired portion of bone tissue. Other connecting structure is provided to securely and releasably link the imaging marker with the base. For example, in the illustrated embodiment, the end of the base opposite the threaded portion terminates in asocket head 38 which contains a socket-like recess 36. (It is anticipated that the base will be implanted into bone with the aid of an insertion tool that twists the base into the bone or into a hole provided in the bone. The recess is non-circular so as to better transmit the torque provided by such an insertion tool.) Just beneath thesocket head 38 are a plurality (as seen in FIG. 3c, three) ofgrooves 34. As shall be further explained below, thesocket 38 and thegrooves 34 provide for the secure and releasable attachment of the imaging marker portion with base portion. - The imaging marker portion of the temporary fiducial marker assembly may consist of two principal portions, a
cylinder 12 and a cap 16 (see FIGS. 4A - 4C). Thecylinder 12 contains acavity 14 for receiving a mixture of imaging agents whose composition is determined by the imaging modalities to be employed. While in this version, the vessel containing the imaging agents is preferably cylindrical so as to simplify the process by which the centroid of the corresponding volume of imaging agent is determined, other shapes (such as a box or sphere) could be employed as well. Thecylinder 12 is closed at one end and open at the other to allow for the introduction of the imaging agents. In one version of the device, acap 16 is used to seal off the open end of the cylinder once the imaging agents have been added to the cylinder. In this version, the cap may be cemented or welded into place. The cap may be provided with aplug portion 24 that protrudes into and thereby helps seal off thecavity 14 of thecylinder 12 against leakage of the imaging agents. Other conventional filling and sealing techniques, such as blow-molding, ultrasonic welding, or heat sealing, may be used. - Where a cap is employed, it may be provided with a protruding
boss 20 and a plurality (here, three) ofsnap arms 18, which terminate with inwardly projectingportions 22. The shape and dimensions of the boss are in direct correspondence with the shape and size of thesocket 36 provided in the base 30 so as to properly and securely center the imaging marker on the base. Thesnap arms 18 cooperate with thegrooves 34 of the base 30 so as to detachably secure the imaging marker onto the base. The cooperation of these elements is illustrated in FIGS. 2a and 2 b. While this example shows the use of snap arms, other fastener structure may be provided for attaching the marker to the base (e.g., screw threads, clasps, hooks, etc.). - The dimensions of the temporary fiducial marker assembly will be somewhat dependent on the state of the art of imaging. The greater the sensitivity of the scanner employed, the lesser the quantity of imaging material necessary to provide a suitable image, which in turn makes it possible to reduce the corresponding size of the marker that must be employed to contain the imaging material. The Applicants have found that a base portion approximately 12 mm in length and 2 mm-3 mm in diameter is sufficiently large to provide for the secure placement of the base into the bone beneath the skin. When the clinician prepares the patient for imaging, the base portion is exposed and an imaging marker approximately 6 mm in length is attached to the base; the marker itself may protrude from the scalp and be exposed to air while a scan is performed on the patient. The base and the imaging marker housing are constructed of a bio-compatible organic polymer, such as polyether imide.
- FIG. 5 illustrates a second embodiment of the fiducial marker, which may be left implanted entirely beneath the skin for extended periods of time. The marker comprises a
cylinder 42 defining a space into which is placed one or more desired imaging agents. As noted in the Summary, a cylindrical shape is preferred, because this shape minimizes the size of the incision that must be made for the marker's insertion. It is also the shape that best corresponds to the hole that one drills in the bone to accommodate the marker. The body of the cylinder is sealed off with acap 46 or is otherwise sealed. The body is preferably constructed of an organic polymer known to be well tolerated by the body for extended periods of time, such as polymethyl methacrylate, high density polyethylene, or ceramics such as zirconium oxide and aluminum oxide. The entire marker assembly is small enough for long-term implantation into bone without causing distortion of the bone over time. One exemplary size provides for the marker to be 4 mm in length and 3 mm in diameter. - As shall be explained below, the judicious choice of aqueous imaging agents allows for the construction of a marker that is visible under both CT and MRI imaging modalities. Furthermore, by using a marker that comprises a solid outer portion and an aqueous inner portion, the marker can be located through the use of a non-invasive transcutaneous detection system, such as one employing ultrasound to detect the presence of the solid-liquid interface between the aqueous core and the solid outer portion.
- Because the fiducial marker assembly is to be used in a variety of imaging modalities, the use of solid metal is eschewed throughout. The presence of metal may cause unwanted artifacts and image distortion in the image, and may impede efforts to localize the marker (i.e., locate and identify its centroid). The properties characteristic of solid metal, such as high electrical conductivity, paramagnetism, and, for some metals, ferromagnetism, are generally inappropriate for use in MRI.
- Although metals have been used in the past as CT markers, they are often generally less than optimal because the high linear attenuation of metals may cause unwanted image artifacts, such as starbursts. While these artifacts can be reduced somewhat by reducing the size of the markers, this reduction in size also reduces the accuracy with which the location of the marker can be determined. In MRI, metals cause disturbances in the local magnetic field (the so-called “susceptibility” artifact) which diminish the image intensity and physically shift the position of the image. Such physical phenomena are unsuitable in a fiducial marker. The choice of materials selected as imaging agents is therefore driven by the physics underlying the image modalities that are employed.
- In CT studies of human tissue, the brightest anatomical features imaged are bone, which attenuates X-rays more strongly than other tissue. This attenuation is characterized by the so-called “linear attenuation coefficient,” which measures the X-ray attenuation per unit of path length. The linear attenuation coefficient increases with increasing electron density (the number of electrons per unit of volume). In order for an X-ray CT imager to produce pixels brighter than bone when imaging a material (such as that of a marker), the material being scanned must have an electron density that is greater than that of bone. Therefore, one approach to enhancing the absorption of X-rays is to increase the electron density per unit volume. This can be accomplished by adding compounds having atoms of high atomic number (Z) to the imaged object, or by substantially increasing the density of the material being scanned. Any high Z value atom suffices. Suitable materials include barium, iodine, titanium, tantalum, silver, gold, platinum, and stainless steel. These materials may be solid, or dissolved as ions in biologically compatible fluids. However, as noted above, the use of solid metal in a fiducial marker tends to create artifacts that degrade the ability of the marker to be used as a true fiducial. These artifacts are higher for markers that have higher linear attenuation coefficients. They are also higher for markers of larger sizes. In particular, for a given linear attenuation coefficient, if the shape and size of the marker is altered so that there is a longer path length through the marker, the tendency to cause an image artifact increases. It is therefore necessary to provide the high z value material in a diluted form.
- One approach to providing an imageable marker of appropriate size that does not yield unwanted artifacts is to dope the marker housing with a CT imaging agent. For example, the housing for the marker, which is normally made of organic polymers, can have barium added as a salt. Alternatively, titanium dioxide may be added to the polymeric housing. Salts of gold or of platinum are also effective materials for rendering the housing shell radio-opaque and thus imageable under CT scanning. Concentrations of these metal salts of up to about 400 mg/ml can be used in the markers without causing appreciable image artifacts. It must be born in mind that it will still be necessary to locate the geometric center of the marker housing so doped; therefore, the geometry of the doped housing should preferably be configured so that its center will be coincident with the center of the volume of any other imaging agent used to accommodate other imaging modalities.
- Another approach to providing high Z value agents without resorting to the use of solid metal is to provide them in the form of an aqueous solution. Aqueous solutions of compounds having high Z atoms, such as barium, iodine, titanium, tantalum, silver, platinum, and iron can be used as imaging agents in the fiducial marker of this invention. In particular, compounds of iodine and silver have been found to be effective for this purpose.
- For example, in certain preferred embodiments, an aqueous solution of an iodine containing organic molecule with an effective iodine concentration of between about 50 to about 600 mg/ml provides an effective CT imaging agent. In another preferred embodiment, silver nitrate dissolved in water at concentrations of between about 100 mg/ml to about 600 mg/ml is effective. Either solution will be effective in CT at imaging the volume defined by the marker cavity.
- By judicious choice of a high-Z aqueous solution, it is possible to create a set of markers having absorption properties in X-ray CT that are anywhere between those of water and 15 times those of bone. However, the effect of these agents on MRI imaging must also be considered, as must the additional requirements that MRI imaging presents.
- For example, the use of aqueous solutions where only CT imaging is contemplated is optional—other carriers, such as oils, could be used as carriers for high Z-number elements. However, this is not the case with respect to MRI. The accurate location of MRI markers in biological tissue must be done with an aqueous imaging agent. Substances other than water exhibit different resonance frequencies, or chemical shifts, and will appear in the image displaced from their true location. Therefore, where a common liquid carrier is to be used both for CT as well as MRI imaging agents, it should be water. (The phenomenon of chemical shift is further described in the literature and is well known to practitioners in the art - see e.g., “Edge Artifacts in MR Images: Chemical Shift Effect,”Journal of Computer Assisted Tomography 9(2):252-257 (1985).)
- The physics of MRI scanning must further be considered. Pure water is characterized in proton nuclear magnetic resonance by a high spin density and long T1 and T2 values. The relaxation times are in the range of two to four seconds. MRI images are partly based on spin density as well as T1 and T2. The effect of spin density on image brightness is linear; reducing the spin density by one half reduces the brightness by one half. The effects of T1 and T2 are exponential; for example, altering these by one half results in a change of 86% in the brightness in the image. These factors may be summarized mathematically as follows:
- I=NC(e−(TE/T2)) (1−e−(TR/T1))
- where I=signal intensity, N=spin density, the parameters TR and TE are the repetition time and the echo time determined by the radio frequency and gradient pulses employed, and C is a constant of proportionality that depends on the scanner and the pulses employed.
- These three parameters, T1, T2, and spin density, can be altered by the addition of chemicals selected for their physical properties in solution. One such property is paramagnetism, in which the added material has an unpaired electron in its electron configuration. Such agents shorten the relaxation times T1 and T2 drastically. Another such property is viscosity. Other chemicals may be added to the solution for their ability to alter the viscosity of a solution, even to a point of making a gel. viscosity is an important consideration, because it is inversely correlated with T2. The more viscous a solution, the greater the number of bonds that are present and the less able the hydrogen nuclei are to react and respond to the magnetic field, which results in a dimmer image. These viscosity enhancing agents dilute the water in the solution, thereby reducing the spin density, and reduce the relaxation times T1 and T2. Whatever the added material, T1 will always be equal to or greater than T2.
- Because of the small concentrations of MRI imaging agents appropriate for MRI enhancements, these agents have no significant effect on the CT imaging agent. However, the efficacy of an MRI imaging agent may be obscured by the presence of a CT imaging agent. The MR image is modulated by the cumulative effects of all solutes added to an aqueous medium. This modulation is due to interactions with the hydrogen atoms in water which provide the MR signal. The general effects of three typical CT imaging agents, of one typical MR imaging agent, and of selected combinations of these two types of agents are presented below.
- In accordance with the above discussion, it has been determined that silver nitrate, which, as noted above, provides a suitable image under CT scans when provided in concentrations up to about 600 mg/ml, reduces the observed spin density (and hence reduces the brightness of the MR image) by up to 50%. At a preferred concentration of about 600 mg/ml, the observed T1 and T2 values are about 1 second. As the concentration of silver nitrate decreases, the T1 and T2 values approach those of pure water. This observed effect affords the opportunity to provide a variety of marker compositions based on silver nitrate (as the CT agent) to create differing contrast levels with respect to human tissue under MRI.
- A solution of iohexol (a non-ionic X-ray CT imaging agent) in concentrations of up to about 600 mg/ml of iodine also reduces the observed spin density by up to 50%. At a concentration of 150 mg of iodine per ml of aqueous solution, the observed T1 value is 300-400 milliseconds, and the observed T2 value is 100-120 milliseconds. The effect on these parameters is in accord with similar effects noted from increasing the viscosity of aqueous solutions. Over the entire range of iohexol concentrations, it has been determined that one can alter the spin density by 50%, change the T1 value from 4 seconds to 0.15 seconds, and the T2 value from 4 seconds to 0.04 seconds. Thus, iohexol too, may be used to provide a variety of marker compositions to create different contrast levels with respect to human tissue under MRI.
- A solution of iothalamate meglumine (an ionic X-ray CT imaging agent) in concentrations up to about 600 mg/ml of iodine reduces the observed spin density by factors ranging up to 75%. At a concentration of 175 mg of iodine per ml of aqueous solution, the observed T1 value is 1200-1500 milliseconds, and the observed T2 value is 300-350 milliseconds. The solution is not viscous at this concentration. Over the entire range of iothalamate meglumine concentrations it has been determined that one can alter proton spin by 75%, change T1 value from 4 seconds to 1 second, and the T2 value from 4 seconds to 200 milliseconds. Thus iothalamate meglumine may be used to provide a variety of marker compositions to create different contrast with respect to human tissue.
- Within limits, one can prepare solutions of reduced spin density in which T1 is equal to T2, and solutions providing spin density in which T1 is greater that T2. T1 and T2 values of these altered solutions range from 1 millisecond to 4 seconds, while the spin density ranges from 0 molar (no water at all) to 111 molar in hydrogen (pure water). The instant invention identifies a number of substances suitable for use in MRI imaging in fiducial markers. One preferred suitable MRI imaging agent is gadopentetate dimeglumine. Another possible MRI imaging agent is gadoteridol. (Each of the aforementioned substances has received FDA approval for use as an injectable MRI imaging agent.) Other possible agents for use as MRI imaging agents include Ferric Chloride (FeCl3) and Copper Sulfate (CuSO4) in concentrations of between 0.5 mM and 5 mM. For a more complete listing of contrast agents and their properties, see
chapter 14 of Magnetic Resonance Imaging, 2nd ed., edited by Stark and Bradley, 1992, the contents of which are herein incorporated by reference. - A solution of gadopentetate dimeglumine-DPTA (an injectable MR contrast agent) in concentrations up to about 0.5 mM (millimolar) is seen to have little effect on the observed spin density of the solution. At a concentration of 0.5 mM, the observed T1 value is 50 to 100 milliseconds, and the observed T2 value is 8 to 15 milliseconds. Over the entire range of concentrations one observes spin density of 111 molar in hydrogen (water). T1 varies from 50 milliseconds to 4 seconds, and T2 varies from 8 milliseconds to 4 seconds. This is in accord with the reported effect of the paramagnetic material. By varying the marker compositions based on the gadopentetate compound, it is possible to create a variety of different contrasts with respect to human tissue.
- The four solutions just discussed were based on one solute in water. To provide a multi-modality marker, binary mixtures of CT and MR contrast agents are considered. It has been observed that binary combinations of gadopentetate-DPTA with any of the other chemical compounds set forth produce a synergistic effect. The matrix of possibilities for altering spin density, T1 and T2, by varying the concentration of MRI and CT imaging agents, enhances the ability to tailor solutions to give maximum contrast in all three types of MR image parameters. For example, with respect to the permanent marker, iothalamate meglumine at a concentration of 175 mg/ml combined with gadopentetate meglumine-DPTA at 0.5 mM creates a solution with the following MR properties: a spin density corresponding to 75-80 molar water, T1 value of 400-500 milliseconds, and a T2 value of 150-200 milliseconds. A variety of other binary compositions permit one to create many different ratios of spin density, T1 and T2 values.
- Hence, as these examples suggest, it is possible to create a set of MR markers with any combination of spin density, T1 and T2 that are smaller in magnitude than those of water. The optimum values of these parameters as specified by the marker application dictate the composition of the solution.
- For one marker to be optimized for both MRI and CT, the imaging agents and their concentrations must be selected such that the solution and/or housing may be differentiated in the X-ray by its radio-opacity and at the same time be differentiated in the MRI by its MRI parameter set—spin density, T1, and T2. As noted above, it is known that aqueous solutions of compounds based on high Z number elements will provide the necessary degree of radio-opacity for CT imaging. It is also known that such substances may reduce the imaging efficacy of compounds selected for their use as MRI contrast agent, such as gadopentetate dimeglumine-DPTA. In order to combine the two agents in an effective manner, they are mixed together in varying concentration and tested under both CT and MRI scans until one has empirically determined a concentration of each that provides a marker that is acceptably imageable under both modalities.
- As a result of such a course of testing, the Applicants have identified two preferred binary mixtures that meet these requirements when used in the permanent marker; these are iothalamate meglumine (175 mg of iodine/ml) with gadopentetate dimeglumine-DPTA (0.5 mM) and silver nitrate (350 mg/ml) with gadopentetate dimeglumine-DPTA (0.5 mM). In the case of the temporary marker, the concentrations of the CT imaging agents are reduced to 165 mg of iodine per ml of aqueous solution of iothalamate meglumine and 200 mg/ml of silver nitrate respectively.
- The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. For example, the aqueous solutions used as the carrier for the imaging agents could have the characteristics of a gel. The imaging agents could be provided as mixtures of three or more compounds selected to optimize particular imaging characteristics.
- The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. For example, a flatter, more disk-like marker than that which is shown in the figures may be employed. Increasing the largest dimension of X-ray traversal boosts the brightness of the image in CT. It also allows one to take CT scans with thicker slices in which the image of the marker does not become lost in the corresponding pixel. This is especially useful in trauma cases, when there is not sufficient time for more refined views.
- In another variant, the imaging agents discussed above can be relied upon for one imaging mode and another technique relied on for locating the marker in a second imaging mode. For example, one may image a marker under a first modality (e.g., MRI) using the imaging agents discussed above, and then locate the marker in the image space generated by a second imaging modality (e.g., CT) by physically locating the marker in the physical space of the second imaging machine. For example, robotic arms such as are disclosed in U.S. Pat. No. 5,142,930 (the contents of which are herein incorporated by reference) or U.S. Pat. No. 4,991,579 could be used for this purpose, since in the course of a scan the addresses of each point in image space are generally defined with respect to the imaging machine and hence to any arm (such as that disclosed in the '930 patent) or other device whose location is clearly defined with respect to that machine. One may then label the corresponding point in image space as containing the location of marker, even where it is not directly imageable in that imaging mode.
Claims (34)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/742,411 US6333971B2 (en) | 1995-06-07 | 2000-12-22 | Fiducial marker |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48070995A | 1995-06-07 | 1995-06-07 | |
US09/742,411 US6333971B2 (en) | 1995-06-07 | 2000-12-22 | Fiducial marker |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US48070995A Division | 1995-06-07 | 1995-06-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
US20010004395A1 true US20010004395A1 (en) | 2001-06-21 |
US6333971B2 US6333971B2 (en) | 2001-12-25 |
Family
ID=23909037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/742,411 Expired - Fee Related US6333971B2 (en) | 1995-06-07 | 2000-12-22 | Fiducial marker |
Country Status (1)
Country | Link |
---|---|
US (1) | US6333971B2 (en) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040019265A1 (en) * | 2002-07-29 | 2004-01-29 | Mazzocchi Rudy A. | Fiducial marker devices, tools, and methods |
US20040075048A1 (en) * | 2002-10-22 | 2004-04-22 | Zyromski Kristiana E. | Multimodal imaging sources |
US20040167393A1 (en) * | 2003-02-25 | 2004-08-26 | Solar Matthew S. | Fiducial marker devices, tools, and methods |
US20050033157A1 (en) * | 2003-07-25 | 2005-02-10 | Klein Dean A. | Multi-modality marking material and method |
US20050043735A1 (en) * | 2003-08-21 | 2005-02-24 | Osteomed L.P. | Bone anchor system |
WO2005018456A1 (en) * | 2003-08-25 | 2005-03-03 | Koninklijke Philips Electronics N.V. | Calibration image alignment in a pet-ct system |
US20050154293A1 (en) * | 2003-12-24 | 2005-07-14 | Margo Gisselberg | Implantable marker with wireless signal transmitter |
US20050234336A1 (en) * | 2004-03-26 | 2005-10-20 | Beckman Andrew T | Apparatus and method for marking tissue |
JP2007527284A (en) * | 2004-02-25 | 2007-09-27 | クレルク、ルネ ド | Method for detecting the position of a dental implant and a marker element |
US20080262345A1 (en) * | 2003-07-21 | 2008-10-23 | The John Hopkins University | Image registration of multiple medical imaging modalities using a multiple degree-of-freedom-encoded fiducial device |
US20080317312A1 (en) * | 2005-07-08 | 2008-12-25 | Pnn Medical A/S | Method of Guiding an Irradiation Equipment |
EP2056914A1 (en) * | 2006-07-05 | 2009-05-13 | Strålen AB | Reference means for precision radiation treatment |
US7787934B2 (en) | 2002-07-29 | 2010-08-31 | Medtronic, Inc. | Fiducial marker devices, tools, and methods |
WO2012007456A1 (en) * | 2010-07-12 | 2012-01-19 | Ge Healthcare As | X-ray imaging at low contrast agent concentrations and/or low dose radiation |
WO2013104690A1 (en) * | 2012-01-11 | 2013-07-18 | Ge Healthcare As | X-ray imaging contrast media with low iodine concentration and x-ray imaging process |
US20130256559A1 (en) * | 2012-03-30 | 2013-10-03 | General Electric Company | Method and apparatus for aligning a multi-modality imaging system |
US20140049629A1 (en) * | 2011-04-29 | 2014-02-20 | The Johns Hopkins University | Sytem and method for tracking and navigation |
US20140187912A1 (en) * | 2012-12-27 | 2014-07-03 | Metal Industries Research&Development Centre | Positioning device, image projecting system and method for overlapping images |
WO2014154861A1 (en) * | 2013-03-28 | 2014-10-02 | Elekta Ab | Markers, phantoms and associated methods for calibrating imaging systems |
US20150285941A1 (en) * | 2012-11-13 | 2015-10-08 | Kromek Limited | Identification of materials |
US20150300967A1 (en) * | 2012-11-13 | 2015-10-22 | Kromek Limited | Identification of materials from a hydrogen to electron ratio |
EP3005974A4 (en) * | 2013-05-31 | 2017-01-18 | Josep Soler Cegarra | Dental implant |
CN109350088A (en) * | 2018-09-26 | 2019-02-19 | 河北海棠花医疗器械有限公司 | Multi-modal index point |
US10537393B2 (en) | 2014-04-04 | 2020-01-21 | Izi Medical Products, Llc | Medical device for surgical navigation system and corresponding method of manufacturing |
WO2021211650A1 (en) * | 2020-04-14 | 2021-10-21 | Mobius Imaging, Llc | Methods and systems for performing image registration in a computer-assisted surgery system |
US11612451B2 (en) | 2020-02-06 | 2023-03-28 | Patrick C. Bell | Dental scanning methods for analyzing jaws |
US11744530B2 (en) | 2020-09-15 | 2023-09-05 | Patrick C. Bell | Radiographic dental jigs and associated methods |
US11963829B2 (en) | 2020-02-06 | 2024-04-23 | Patrick C. Bell | Fiducial markers for analyzing human jaws |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6381485B1 (en) | 1999-10-28 | 2002-04-30 | Surgical Navigation Technologies, Inc. | Registration of human anatomy integrated for electromagnetic localization |
WO2001064124A1 (en) * | 2000-03-01 | 2001-09-07 | Surgical Navigation Technologies, Inc. | Multiple cannula image guided tool for image guided procedures |
WO2002078510A2 (en) * | 2001-03-23 | 2002-10-10 | Alcove Surfaces Gmbh | Aluminium implant and use thereof |
WO2003025621A1 (en) * | 2001-09-21 | 2003-03-27 | Radqual, Llc | Spot marker for use in imaging procedures |
US6616604B1 (en) | 2002-04-05 | 2003-09-09 | Allegiance Corporation | Surgical retractor securing apparatus |
US6761679B2 (en) * | 2002-07-02 | 2004-07-13 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Embedded radiation emitter for the localization and dosimetry of brachytherapy seed implants |
US20060281991A1 (en) * | 2003-05-09 | 2006-12-14 | Fitzpatrick J M | Fiducial marker holder system for surgery |
US7862570B2 (en) | 2003-10-03 | 2011-01-04 | Smith & Nephew, Inc. | Surgical positioners |
US7764985B2 (en) | 2003-10-20 | 2010-07-27 | Smith & Nephew, Inc. | Surgical navigation system component fault interfaces and related processes |
ATE495706T1 (en) | 2003-11-14 | 2011-02-15 | Smith & Nephew Inc | ADJUSTABLE SURGICAL CUTTING SYSTEMS |
EP1737375B1 (en) | 2004-04-21 | 2021-08-11 | Smith & Nephew, Inc | Computer-aided navigation systems for shoulder arthroplasty |
US8442623B2 (en) * | 2004-10-13 | 2013-05-14 | Suros Surgical Systems, Inc. | Site marker visible under multiple modalities |
US8060183B2 (en) | 2004-10-13 | 2011-11-15 | Suros Surgical Systems, Inc. | Site marker visible under multiple modalities |
US20060079805A1 (en) * | 2004-10-13 | 2006-04-13 | Miller Michael E | Site marker visable under multiple modalities |
US8280486B2 (en) | 2004-10-13 | 2012-10-02 | Suros Surgical Systems, Inc. | Site marker visable under multiple modalities |
WO2006064400A2 (en) * | 2004-12-15 | 2006-06-22 | Koninklijke Philips Electronics, N.V. | Registration of multi-modality images |
CA2601976A1 (en) | 2005-02-22 | 2006-08-31 | Smith & Nephew, Inc. | In-line milling system |
US11241296B2 (en) | 2005-11-17 | 2022-02-08 | Breast-Med, Inc. | Imaging fiducial markers and methods |
US7702378B2 (en) | 2005-11-17 | 2010-04-20 | Breast-Med, Inc. | Tissue marker for multimodality radiographic imaging |
US20070225595A1 (en) * | 2006-01-17 | 2007-09-27 | Don Malackowski | Hybrid navigation system for tracking the position of body tissue |
DE102006037776B3 (en) * | 2006-08-11 | 2008-02-21 | Siemens Ag | Device for calibrating a magnetic resonance system with PET function |
US20080183221A1 (en) * | 2006-12-06 | 2008-07-31 | Spinal Modulation, Inc. | Hard tissue anchors and delivery devices |
EP1955733A1 (en) * | 2007-02-06 | 2008-08-13 | Siemens Schweiz AG | Device for the physical location of a moveable body part |
TW200833298A (en) * | 2007-02-09 | 2008-08-16 | Been-Der Yang | Surgical positioning device |
US8934961B2 (en) * | 2007-05-18 | 2015-01-13 | Biomet Manufacturing, Llc | Trackable diagnostic scope apparatus and methods of use |
WO2009009760A1 (en) * | 2007-07-11 | 2009-01-15 | Board Of Regents, The University Of Texas System | Seeds and markers for use in imaging |
US8489177B2 (en) * | 2008-07-16 | 2013-07-16 | Dilon Technologies, Inc. | Fiducial marker and method for gamma guided stereotactic localization |
US9936892B1 (en) | 2009-05-04 | 2018-04-10 | Cortex Manufacturing Inc. | Systems and methods for providing a fiducial marker |
US20110028831A1 (en) * | 2009-07-30 | 2011-02-03 | Kent James P | Permanently visible implantable fiduciary tissue marker |
US20110097134A1 (en) * | 2009-10-23 | 2011-04-28 | Allen Eric Evan | Radiocontrast Highlighter |
US8435033B2 (en) | 2010-07-19 | 2013-05-07 | Rainbow Medical Ltd. | Dental navigation techniques |
BR112013018534B1 (en) | 2011-01-20 | 2021-04-06 | Board Of Regents, The University Of Texas System | CONTRAST AGENT, ITS PREPARATION METHODS, AND COMBINATION PRODUCT |
US8798716B1 (en) * | 2011-11-03 | 2014-08-05 | Solstice Corporation | Fiducial markers and related methods |
CN103126702B (en) * | 2011-12-05 | 2015-03-11 | 陈兆秋 | External marking point for multimodal medical image fusion |
JP5993184B2 (en) * | 2012-04-04 | 2016-09-14 | オリンパス株式会社 | Fluorescence observation apparatus and method of operating fluorescence observation apparatus |
JP6032729B2 (en) * | 2012-05-08 | 2016-11-30 | 国立研究開発法人理化学研究所 | Imaging markers and their use |
US10908238B2 (en) * | 2013-10-25 | 2021-02-02 | Brainlab Ag | Magnetic resonance coil unit and method for its manufacture |
PT2907474T (en) * | 2014-02-18 | 2017-11-14 | Accurate Fit S L | Post for modelling dental implants by means of a radiologic test. |
US9861449B2 (en) | 2014-04-01 | 2018-01-09 | University Of Utah Research Foundation | Radiopaque marking implement |
US9795455B2 (en) | 2014-08-22 | 2017-10-24 | Breast-Med, Inc. | Tissue marker for multimodality radiographic imaging |
CA2964512C (en) * | 2014-10-14 | 2018-04-24 | Synaptive Medical (Barbados) Inc. | Patient reference tool |
US11090130B2 (en) * | 2015-10-09 | 2021-08-17 | Oregon State University | Fiducial marker for computed tomography and magnetic resonance imaging |
US10327869B2 (en) | 2015-10-21 | 2019-06-25 | Biomet 3I, Llc | Attachment members with internally located radiopaque information markers for CT scan |
CN108064396B (en) * | 2017-05-27 | 2021-04-30 | 上海联影医疗科技股份有限公司 | System and method for compensating for couch subsidence in image-guided radiation therapy |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3836776A (en) | 1973-03-01 | 1974-09-17 | E Gullekson | Three dimensional x-ray opaque foreign body marker device |
US4310507A (en) | 1978-08-02 | 1982-01-12 | Eastman Kodak Company | Contrast agent for radiography |
US4608977A (en) | 1979-08-29 | 1986-09-02 | Brown Russell A | System using computed tomography as for selective body treatment |
US4615876A (en) | 1983-04-25 | 1986-10-07 | Curators Of The University Of Missouri | Macrocyclic complexes of technetium-99m for use as diagnostic radionuclides |
US4618978A (en) | 1983-10-21 | 1986-10-21 | Cosman Eric R | Means for localizing target coordinates in a body relative to a guidance system reference frame in any arbitrary plane as viewed by a tomographic image through the body |
US4615879A (en) | 1983-11-14 | 1986-10-07 | Vanderbilt University | Particulate NMR contrast agents for gastrointestinal application |
CH661199A5 (en) | 1983-12-22 | 1987-07-15 | Sulzer Ag | MARKING IMPLANT. |
US4728575A (en) | 1984-04-27 | 1988-03-01 | Vestar, Inc. | Contrast agents for NMR imaging |
US4583538A (en) | 1984-05-04 | 1986-04-22 | Onik Gary M | Method and apparatus for stereotaxic placement of probes in the body utilizing CT scanner localization |
GB8413772D0 (en) | 1984-05-30 | 1984-07-04 | Nyegaard & Co As | Chemical compounds |
GB8415265D0 (en) | 1984-06-15 | 1984-07-18 | Ici Plc | Device |
US4612930A (en) | 1985-03-19 | 1986-09-23 | Bremer Paul W | Head fixation apparatus including crown and skull pin |
US4675173A (en) | 1985-05-08 | 1987-06-23 | Molecular Biosystems, Inc. | Method of magnetic resonance imaging of the liver and spleen |
US4669481A (en) | 1985-12-16 | 1987-06-02 | Vanderbilt University | Method of magnetic resonance imaging using chromium-labelled red blood cells |
US4729892A (en) | 1986-03-21 | 1988-03-08 | Ciba-Geigy Corporation | Use of cross-linked hydrogel materials as image contrast agents in proton nuclear magnetic resonance tomography and tissue phantom kits containing such materials |
US5055288A (en) | 1987-06-26 | 1991-10-08 | Advanced Magnetics, Inc. | Vascular magnetic imaging method and agent comprising biodegradeable superparamagnetic metal oxides |
US4826487A (en) | 1987-05-04 | 1989-05-02 | Victory Engineering Company | Alignment button for stereotaxic plug and method of using the same |
US4989608A (en) | 1987-07-02 | 1991-02-05 | Ratner Adam V | Device construction and method facilitating magnetic resonance imaging of foreign objects in a body |
US4991579A (en) | 1987-11-10 | 1991-02-12 | Allen George S | Method and apparatus for providing related images over time of a portion of the anatomy using fiducial implants |
US4927624A (en) | 1987-11-19 | 1990-05-22 | The University Of Rochester | Clay magnetic resonance contrast agents for gastrointestinal comsumption or introduction |
US5023072A (en) | 1988-08-10 | 1991-06-11 | University Of New Mexico | Paramagnetic/superparamagnetic/ferromagnetic sucrose sulfate compositions for magnetic resonance imaging of the gastrointestinal tract |
US4860331A (en) | 1988-09-12 | 1989-08-22 | Williams John F | Image marker device |
US5178146A (en) | 1988-11-03 | 1993-01-12 | Giese William L | Grid and patient alignment system for use with MRI and other imaging modalities |
FI80585C (en) | 1988-11-11 | 1990-07-10 | Instrumentarium Oy | ARRANGEMANG FOER UNDERSOEKNING AV ETT OBJEKT. |
US5099846A (en) | 1988-12-23 | 1992-03-31 | Hardy Tyrone L | Method and apparatus for video presentation from a variety of scanner imaging sources |
US5019370A (en) | 1989-07-10 | 1991-05-28 | University Of Kentucky Research Foundation | Biodegradable, low biological toxicity radiographic contrast medium and method of x-ray imaging |
US5120527A (en) | 1989-10-19 | 1992-06-09 | King Chuen Peter Li | Paramagnetic oil emulsions as mri contrast agents |
ES2085885T3 (en) | 1989-11-08 | 1996-06-16 | George S Allen | MECHANICAL ARM FOR INTERACTIVE SURGERY SYSTEM DIRECTED BY IMAGES. |
US5046498A (en) | 1991-01-16 | 1991-09-10 | Union Carbide Industrial Gases Technology Corporation | Magnetic resonance human medical and veterinary imaging method |
US5401489A (en) * | 1991-05-01 | 1995-03-28 | University Of New Mexico | Biomodulators as universal imaging agents |
US5138165A (en) | 1991-10-31 | 1992-08-11 | Rockwell International Corporation | Three dimensional positron emission tomography system |
US5368030A (en) | 1992-09-09 | 1994-11-29 | Izi Corporation | Non-invasive multi-modality radiographic surface markers |
US5469847A (en) | 1992-09-09 | 1995-11-28 | Izi Corporation | Radiographic multi-modality skin markers |
DE4233978C1 (en) | 1992-10-08 | 1994-04-21 | Leibinger Gmbh | Body marking device for medical examinations |
GB9501560D0 (en) * | 1995-01-26 | 1995-03-15 | Nycomed Imaging As | Contrast agents |
-
2000
- 2000-12-22 US US09/742,411 patent/US6333971B2/en not_active Expired - Fee Related
Cited By (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7787934B2 (en) | 2002-07-29 | 2010-08-31 | Medtronic, Inc. | Fiducial marker devices, tools, and methods |
US20040019265A1 (en) * | 2002-07-29 | 2004-01-29 | Mazzocchi Rudy A. | Fiducial marker devices, tools, and methods |
US6927406B2 (en) | 2002-10-22 | 2005-08-09 | Iso-Science Laboratories, Inc. | Multimodal imaging sources |
US20040075048A1 (en) * | 2002-10-22 | 2004-04-22 | Zyromski Kristiana E. | Multimodal imaging sources |
EP1413251A1 (en) * | 2002-10-22 | 2004-04-28 | Iso-Science Laboratories, Inc. | Multimodal imaging marker |
US20070225599A1 (en) * | 2003-02-25 | 2007-09-27 | Image-Guided Neurologics, Inc. | Fiducial marker devices, tools, and methods |
US20040167393A1 (en) * | 2003-02-25 | 2004-08-26 | Solar Matthew S. | Fiducial marker devices, tools, and methods |
US7720522B2 (en) | 2003-02-25 | 2010-05-18 | Medtronic, Inc. | Fiducial marker devices, tools, and methods |
US8185184B2 (en) | 2003-02-25 | 2012-05-22 | Medtronic, Inc. | Fiducial marker devices, tools, and methods |
US8073530B2 (en) | 2003-02-25 | 2011-12-06 | Medtronic, Inc. | Fiducial marker devices, tools, and methods |
US20100217120A1 (en) * | 2003-02-25 | 2010-08-26 | Medtronic, Inc. | Fiducial Marker Devices, Tools, and Methods |
US20040167391A1 (en) * | 2003-02-25 | 2004-08-26 | Solar Matthew S. | Fiducial marker devices, tools, and methods |
US8032204B2 (en) | 2003-02-25 | 2011-10-04 | Medtronic, Inc. | Fiducial marker devices, tools, and methods |
US20150216621A1 (en) * | 2003-07-21 | 2015-08-06 | The Johns Hopkins University | Image registration of multiple medical imaging modalities using a multiple degree-of-freedom-encoded fiducial device |
US8948471B2 (en) * | 2003-07-21 | 2015-02-03 | The John Hopkins University | Image registration of multiple medical imaging modalities using a multiple degree-of-freedom-encoded fiducial device |
US20080262345A1 (en) * | 2003-07-21 | 2008-10-23 | The John Hopkins University | Image registration of multiple medical imaging modalities using a multiple degree-of-freedom-encoded fiducial device |
US20050033157A1 (en) * | 2003-07-25 | 2005-02-10 | Klein Dean A. | Multi-modality marking material and method |
US7662157B2 (en) | 2003-08-21 | 2010-02-16 | Osteomed L.P. | Bone anchor system |
US20050043735A1 (en) * | 2003-08-21 | 2005-02-24 | Osteomed L.P. | Bone anchor system |
US20080212859A1 (en) * | 2003-08-25 | 2008-09-04 | Da Silva Angela J | Calibration Image Alignment in a Pet-Ct System |
US7697738B2 (en) | 2003-08-25 | 2010-04-13 | Koninklijke Philips Electronics N.V. | Calibration image alignment in a PET-CT system |
WO2005018456A1 (en) * | 2003-08-25 | 2005-03-03 | Koninklijke Philips Electronics N.V. | Calibration image alignment in a pet-ct system |
US20050154293A1 (en) * | 2003-12-24 | 2005-07-14 | Margo Gisselberg | Implantable marker with wireless signal transmitter |
US8196589B2 (en) * | 2003-12-24 | 2012-06-12 | Calypso Medical Technologies, Inc. | Implantable marker with wireless signal transmitter |
JP2007527284A (en) * | 2004-02-25 | 2007-09-27 | クレルク、ルネ ド | Method for detecting the position of a dental implant and a marker element |
US20050234336A1 (en) * | 2004-03-26 | 2005-10-20 | Beckman Andrew T | Apparatus and method for marking tissue |
US8391570B2 (en) | 2005-07-08 | 2013-03-05 | Pnn Medical A/S | Method of guiding an irradiation equipment |
US20080317312A1 (en) * | 2005-07-08 | 2008-12-25 | Pnn Medical A/S | Method of Guiding an Irradiation Equipment |
US20090196470A1 (en) * | 2005-07-08 | 2009-08-06 | Jesper Carl | Method of identification of an element in two or more images |
JP2009540972A (en) * | 2005-07-08 | 2009-11-26 | ピーエヌエヌ メディカル エイ/エス | Method for identifying elements in two or more images |
EP2052364A1 (en) * | 2005-07-08 | 2009-04-29 | PNN Medical A/S | Method of identification of an element in two or more images |
EP2056914A1 (en) * | 2006-07-05 | 2009-05-13 | Strålen AB | Reference means for precision radiation treatment |
EP2056914A4 (en) * | 2006-07-05 | 2011-10-26 | Straalen Ab | Reference means for precision radiation treatment |
CN102985114A (en) * | 2010-07-12 | 2013-03-20 | 通用电气医疗集团股份有限公司 | X-ray imaging at low contrast agent concentrations and/or low dose radiation |
WO2012007456A1 (en) * | 2010-07-12 | 2012-01-19 | Ge Healthcare As | X-ray imaging at low contrast agent concentrations and/or low dose radiation |
CN105194692A (en) * | 2010-07-12 | 2015-12-30 | 通用电气医疗集团股份有限公司 | X-ray imaging at low contrast agent concentrations and/or low dose radiation |
US20140049629A1 (en) * | 2011-04-29 | 2014-02-20 | The Johns Hopkins University | Sytem and method for tracking and navigation |
US10426554B2 (en) * | 2011-04-29 | 2019-10-01 | The Johns Hopkins University | System and method for tracking and navigation |
WO2013104690A1 (en) * | 2012-01-11 | 2013-07-18 | Ge Healthcare As | X-ray imaging contrast media with low iodine concentration and x-ray imaging process |
US10004816B2 (en) | 2012-01-11 | 2018-06-26 | Ge Healthcare As | X-ray imaging contrast media with low iodine concentration and X-ray imaging process |
US20130256559A1 (en) * | 2012-03-30 | 2013-10-03 | General Electric Company | Method and apparatus for aligning a multi-modality imaging system |
US8969829B2 (en) * | 2012-03-30 | 2015-03-03 | Scott David Wollenweber | Method and apparatus for aligning a multi-modality imaging system |
US20150300967A1 (en) * | 2012-11-13 | 2015-10-22 | Kromek Limited | Identification of materials from a hydrogen to electron ratio |
US20150285941A1 (en) * | 2012-11-13 | 2015-10-08 | Kromek Limited | Identification of materials |
JP2016501360A (en) * | 2012-11-13 | 2016-01-18 | クロメック リミテッドKromek Limited | Material identification method |
US10175382B2 (en) * | 2012-11-13 | 2019-01-08 | Kromek Limited | Identification of materials |
US9841390B2 (en) * | 2012-11-13 | 2017-12-12 | Kromek Limited | Identification of materials from a hydrogen to electron ratio |
US20140187912A1 (en) * | 2012-12-27 | 2014-07-03 | Metal Industries Research&Development Centre | Positioning device, image projecting system and method for overlapping images |
US10022104B2 (en) | 2013-03-28 | 2018-07-17 | Elekta Ab (Publ) | Markers, phantoms and associated methods for calibrating imaging systems |
WO2014154861A1 (en) * | 2013-03-28 | 2014-10-02 | Elekta Ab | Markers, phantoms and associated methods for calibrating imaging systems |
GB2512384B (en) * | 2013-03-28 | 2016-07-20 | Elekta Ab | Markers, Phantoms and Associated Methods for Calibrating Imaging Systems |
EP3005974A4 (en) * | 2013-05-31 | 2017-01-18 | Josep Soler Cegarra | Dental implant |
US10537393B2 (en) | 2014-04-04 | 2020-01-21 | Izi Medical Products, Llc | Medical device for surgical navigation system and corresponding method of manufacturing |
CN109350088A (en) * | 2018-09-26 | 2019-02-19 | 河北海棠花医疗器械有限公司 | Multi-modal index point |
US11612451B2 (en) | 2020-02-06 | 2023-03-28 | Patrick C. Bell | Dental scanning methods for analyzing jaws |
US11963829B2 (en) | 2020-02-06 | 2024-04-23 | Patrick C. Bell | Fiducial markers for analyzing human jaws |
WO2021211650A1 (en) * | 2020-04-14 | 2021-10-21 | Mobius Imaging, Llc | Methods and systems for performing image registration in a computer-assisted surgery system |
US11744530B2 (en) | 2020-09-15 | 2023-09-05 | Patrick C. Bell | Radiographic dental jigs and associated methods |
Also Published As
Publication number | Publication date |
---|---|
US6333971B2 (en) | 2001-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6333971B2 (en) | Fiducial marker | |
EP0684786B1 (en) | Fiducial marker | |
US9861450B2 (en) | Imaging fiducial markers and methods | |
Maurer et al. | Registration of head volume images using implantable fiducial markers | |
EP0228692B1 (en) | Skin marker | |
US8721660B2 (en) | Stereotactic therapy system | |
US10245446B2 (en) | Marker-flange for MRI-guided brachytherapy | |
Rosenthal et al. | Sacrococcygeal chordoma: magnetic resonance imaging and computed tomography | |
US11241296B2 (en) | Imaging fiducial markers and methods | |
Stokking et al. | Normal fusion for three-dimensional integrated visualization of SPECT and magnetic resonance brain images | |
Martel et al. | Assessment of 3‐dimensional magnetic resonance imaging fast low angle shot images for computer assisted spinal surgery | |
Gray et al. | Low-field magnetic resonance imaging for implant dentistry | |
Maciunas et al. | Positron emission tomography imaging-directed stereotactic neurosurgery. | |
Fujiwara et al. | Multiacquisition variable-resonance image combination selective can improve image quality and reproducibility for metallic implants in the lumbar spine | |
Lee et al. | Automatic registration of MR and SPECT images for treatment planning in prostate cancer | |
Gibon et al. | Stereotactic localization in medical imaging: A technical and methodological review | |
Bergvall et al. | External references of the bicommissural plane | |
Hill et al. | Registration of MR and CT images for clinical applications | |
Graumann et al. | „Neurovision”–a Multimodality Image Fusion Package for Neuroradiological Diagnosis and Neurosurgical Planning | |
Hill et al. | MRI guided intranasal flexible micro-endoscopy | |
Weinhous | The selection of beam orientation and portal aperture using interactively displayed arbitrary-plane sections calculated from 3-D CT data | |
Kacl et al. | MR-Guided Biopsies of the Head and Neck | |
Doria | A primer on imaging | |
Krempien et al. | Synthetic Image Modalities Generated from Matched CT and MRI Data: A New Approach for Using MRI in Brachytherapy | |
Naden | The power of brain waves |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CC | Certificate of correction | ||
AS | Assignment |
Owner name: MARKER, LLC, TENNESSEE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALLEN, M.D., GEORGE S.;REEL/FRAME:015286/0266 Effective date: 20040916 |
|
REMI | Maintenance fee reminder mailed | ||
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
SULP | Surcharge for late payment | ||
FPAY | Fee payment |
Year of fee payment: 8 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20131225 |